Hikma Pharmaceuticals reported first-half 2026 results with group revenue rising 4% to $1,728 million and core operating profit up 9% to $405 million. Reported operating profit jumped 30% to $336 million, reflecting the absence of prior-year legal settlement costs, while core EBITDA increased 8% to $463 million. The company declared an interim dividend of 38 cents per share, up 6%, and has completed $227 million of its $250 million share buyback program. Management reiterated full-year guidance for 2% to 4% constant-currency revenue growth and core operating profit between $720 million and $770 million. Hikma's stock was trading at GBp 1,722.00, up 9.61%.
Hikma Pharmaceuticals PLCH1 results beat with revenue and profit growth, dividend increase, and buyback progress; reiterates guidance.
